United Therapeutics Valuation
| UTH Stock | EUR 338.80 9.10 2.62% |
At this time, the company appears to be overvalued. United Therapeutics has a current Real Value of €292.53 per share. The regular price of the company is €338.8. Our model measures the value of United Therapeutics from inspecting the company fundamentals such as Operating Margin of 0.51 %, shares outstanding of 46.3 M, and Return On Equity of 0.17 as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that United Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of United Therapeutics is based on 3 months time horizon. Increasing United Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the United stock is determined by what a typical buyer is willing to pay for full or partial control of United Therapeutics. Since United Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of United Stock. However, United Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 338.8 | Real 292.53 | Hype 347.9 |
The real value of United Stock, also known as its intrinsic value, is the underlying worth of United Therapeutics Company, which is reflected in its stock price. It is based on United Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of United Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of United Therapeutics helps investors to forecast how United stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of United Therapeutics more accurately as focusing exclusively on United Therapeutics' fundamentals will not take into account other important factors: United Therapeutics Total Value Analysis
United Therapeutics is at this time estimated to have takeover price of 10.24 B with market capitalization of 10.75 B, debt of 800 M, and cash on hands of 1.79 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the United Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
10.24 B | 10.75 B | 800 M | 1.79 B |
United Therapeutics Investor Information
About 98.0% of the company outstanding shares are owned by institutional investors. The book value of United Therapeutics was at this time reported as 104.2. The company has Price/Earnings To Growth (PEG) ratio of 1.0. United Therapeutics recorded earning per share (EPS) of 13.25. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 23rd of September 2009. Based on the key indicators related to United Therapeutics' liquidity, profitability, solvency, and operating efficiency, United Therapeutics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in February.United Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. United Therapeutics has an asset utilization ratio of 32.03 percent. This implies that the Company is making €0.32 for each dollar of assets. An increasing asset utilization means that United Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.United Therapeutics Ownership Allocation
United Therapeutics maintains a total of 46.3 Million outstanding shares. The majority of United Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in United Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in United Therapeutics. Please pay attention to any change in the institutional holdings of United Therapeutics as this could imply that something significant has changed or is about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.United Therapeutics Profitability Analysis
The company reported the revenue of 1.94 B. Net Income was 727.3 M with profit before overhead, payroll, taxes, and interest of 1.78 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates United Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in United Therapeutics and how it compares across the competition.
About United Therapeutics Valuation
The stock valuation mechanism determines United Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of United Therapeutics. We calculate exposure to United Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of United Therapeutics's related companies.United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland. UTD THERAP operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 860 people.
8 Steps to conduct United Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates United Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct United Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain United Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine United Therapeutics' revenue streams: Identify United Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research United Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish United Therapeutics' growth potential: Evaluate United Therapeutics' management, business model, and growth potential.
- Determine United Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate United Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for United Stock analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |